Example: Heart Attack

Search clinical trials for: Fulvestrant

Total 297 results

NCT04460911

Active, not recruiting

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Conditions: Breast Cancer
NCT04460430

Not yet recruiting

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04355520

Not yet recruiting

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Conditions: HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
NCT04352777

Not yet recruiting

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor
NCT04337658

Not yet recruiting

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Conditions: HER2-positive Breast Cancer
NCT04334330

Not yet recruiting

Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Conditions: Breast Cancer; Brain Metastases
NCT04318223

Recruiting

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer
NCT04316169

Not yet recruiting

Hydroxychloroquine (HCQ) in Combination With Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer After a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors

Conditions: Solid Tumor; Advanced Breast Cancer
NCT04305236

Not yet recruiting

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Conditions: Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma
NCT04305496

Recruiting

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
NCT04300790

Not yet recruiting

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Conditions: Breast Cancer
NCT04289974

Recruiting

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Conditions: Breast Cancer
NCT04282031

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Conditions: Advanced Solid Tumor; Breast Neoplasms
NCT04263298

Recruiting

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04258163

Completed

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Conditions: Metastatic Breast Cancer
NCT04256941

Recruiting

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
NCT04224272

Recruiting

A Study of ZW25 With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Conditions: HER2+/HR+ Breast Cancer
NCT04227327

Recruiting

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Conditions: Advanced Breast Cancer
NCT04214288

Recruiting

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
NCT04215003

Not yet recruiting

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Conditions: Breast Cancer
NCT04191499

Recruiting

A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04158362

Recruiting

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Conditions: Cancer Metastatic
NCT04060862

Recruiting

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04053322

Recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
NCT04034589

Recruiting

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04033172

Recruiting

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Conditions: Breast Cancer; HER2-positive Breast Cancer
NCT04031885

Suspended

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04024436

Recruiting

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; FGFR2 Amplification
NCT03959891

Recruiting

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Conditions: Breast Cancer
NCT03939897

Recruiting

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma
NCT03926936

Recruiting

FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

Conditions: Endometrial Stromal Sarcoma; Adenosarcoma of Uterus; Leiomyosarcoma Uterus; Endometrial Cancer; Sex Cord Stromal Tumor; Serous Ovarian Tumor
NCT03927456

Not yet recruiting

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Conditions: Advanced Breast Cancer
NCT03925233

Enrolling by invitation

Breast Cancer Treatment Based on Organ-like Culture

Conditions: Breast Cancer Organoids
NCT03854903

Recruiting

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Conditions: Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer
NCT03820830

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Conditions: Breast Cancer Recurrent
NCT03809988

Recruiting

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Conditions: Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
NCT03803761

Not yet recruiting

Study of a New Drug Combination, Copanlisib and Fulvestrant, in Postmenopausal Women With Advanced Breast Cancer

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Postmenopausal; Prognostic Stage IV Breast Cancer AJCC v8
NCT03778931

Recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Conditions: Breast Cancer
NCT03781063

Recruiting

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation

Conditions: Locally Advanced or Metastatic Breast Cancer
NCT03768479

Unknown status

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; Fulvestrant
NCT03767335

Recruiting

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Conditions: Advanced or Metastatic Breast Cancer
NCT03750396

Recruiting

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Conditions: Breast Cancer; Recurrent Breast Cancer; Stereotactic Body Radiotherapy; Estrogen Receptor Positive Tumor; Her2-negative Tumor; Surgery
NCT03708432

Completed

500mg Fulvestrant in HR+ MBC

Conditions: Breast Cancer
NCT03695341

Completed

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Conditions: Breast Cancer
NCT03691493

Recruiting

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8
NCT03685331

Not yet recruiting

Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation
NCT03643510

Recruiting

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Conditions: Adenocarcinoma of Endometrium
NCT03633331

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Conditions: Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7
NCT03620643

Recruiting

ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study

Conditions: Lobular Breast Carcinoma; Gastric Cancer
NCT03591549

Not yet recruiting

Fulvestrant in Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer

Search clinical trials for: Fulvestrant

Recent CRA jobs

Medical Technologist, Central labs

Clinical Team Manager

Manager, Clinical Data Management

Lab Support Tech

Clinical Trial Coordinator

Principal Programmer Analyst

Digital Project Specialist I

Scientist Biopharm - HPLC (IEX , SEC )

Project Manager - Labs (Metrology)

Director, Project Management - Respiratory Diseases Team